BioCentury
ARTICLE | Clinical News

ALD-301: Phase II started

March 25, 2013 7:00 AM UTC

Cytomedix disclosed in its 4Q12 earnings that it began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate a single administration of 10, 1 mL intramuscular injections of ALD-301 in ab...